Find drug development pipeline and deal Updates information

Lead Product(s): Setrusumab

Therapeutic Area: Genetic Disease

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 14, 2020

Details:

Setrusumab demonstrated a dose dependent increase in both failure load and stiffness at the radius at 12 months, achieving statistical significance in the high dose cohort.

Lead Product(s): Tideglusib

Therapeutic Area: Genetic Disease

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

Trial to assess AMO-02 in treatment of congenital myotonic dystrophy to begin patient enrollment in early 2020.